Background: The large majority of depressed patients fail to remit on the first antidepressant
prescribed. These patients with residual symptoms have higher relapse rates and poorer …

Objective To compare the efficacy and discontinuation of augmentation agents in adult
patients with treatment-resistant depression (TRD). We conducted a systematic review and …

Lithium and triiodothyronin (T3) augmentation of tricyclic agents remains the best studied
strategy. Data converge to demonstrate the efficacy of some atypical antipsychotics as …

BackgroundDepression is considered to have the highest disability burden of all conditions.
Although treatment-resistant depression (TRD) is a key contributor to that burden, there is …

Background: Major depressive disorder (MDD) is a highly burdensome health condition, for
which there are numerous accepted pharmacological and psychological interventions …

Background: Major depressive disorder is a prevalent and disabling illness. Notwithstanding
numerous advances in the pharmacological treatment of depression, approximately 70% of …

Only 50% of depressed patients achieve remission of symptoms after 2 trials of
antidepressants. Therefore one half of patients are considered treatment resistant. Studies …

Objective: To comparatively analyze the efficacy, acceptability, and tolerability of various
augmentation agents in adult patients with treatment-resistant depression. Data Sources: An …

Objective: This article reviews treatment options (eg, augmentation) for depressed patients
with suboptimal clinical responses to an antidepressant. Background: Approximately one …

Despite many advances in pharmacotherapy over the past half centurye, only a fraction of
patients with Major Depressive Disorder (MDD) can achieve remission after the first or …